Evicenter
MarkdownMedical informationP&T meetings
Envudeucitinib (ESK-001)

Moderate-to-severe plaque psoriasis

Also known as FTP-637
Manufacturer
Alumis
Launch
Not announced
Last updated
277 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Moderate-to-severe plaque psoriasis

Humanistic burden and health-related quality of life

17 evidence topics · 12 sources

Itch, pain, fatigue, Dermatology Life Quality Index, and EQ-VAS by severity: U.S. Corrona Psoriasis Registry, 1,529 patients on systemic therapy

“The Corrona Psoriasis Registry is an independent, prospective observational cohort launched in April 2015 in collaboration with the National Psoriasis Foundation, with a target enrolment of 10 000 patients with psoriasis from 200 sites throughout the USA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“1529 adult patients with psoriasis being treated with biological or non-biological systemic psoriasis treatment by 31 May 2016.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“As of 31 May 2016, 1529 patients were enrolled in the registry; the mean age was 50.6 years and 47% were female.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“BSA percentages were categorised as mild (0%–5%), moderate (>5%–10%), severe (>10%–15%) and very severe (>15%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Across BSA categories, mean fatigue scores ranged from 26.5 to 40.2, itching was 24.7 to 55.7 and pain was 15.2 to 41.7. Among IGA categories, mean fatigue scores ranged from 21.9 to 41.8, itching was 12.1 to 57.3 and pain was 7.4 to 44.3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Across BSA and IGA categories, mean DLQI scores ranged from 5.2 to 10.2 and 4.3 to 9.7, respectively. Mean EQ-VAS scores ranged from 62.9 (very severe) to 76.4 (mild) across BSA categories and 62.1 (severe) to 78.8 (clear/almost clear) across IGA categories, with higher scores indicating better health.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Overall DLQI and EQ-VAS scores also worsened with disease severity (p<0.05 for each level of BSA and IGA) (table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Emotional wellbeing, quality of life, self-image, and stigma: U.S. online survey of 793 patients, 2020 to 2021

“In brief, the study was a cross-sectional, quantitative online survey conducted in the USA between 12 November 2020 and 19 May 2021 and comprised a 5-min eligibility screener followed by a 25-min online questionnaire.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“This analysis included 793 US patients with psoriasis; 43% also had PsA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Psoriasis negatively affected emotional well-being and quality of life (QoL) in the majority of patients (87% and 91%, respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Patients stated that their skin symptoms made them feel unattractive (42%), less confident about themselves (37%), ashamed of their skin (35%), depressed (33%), or ashamed of their body (30%; Supplementary Material Fig. S5b).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Many patients also noted that they had experienced stigma and discrimination, such as people not understanding the impact the disease had on the patient’s life (36%), being asked if they were contagious (36%), and being stared at in public (34%) (Supplementary Material Fig. S5a).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote